Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:1.16.3.1 (ceruloplasmin)
 5,074 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

1. Male WAG/Cpb inbred rats fed on rations containing 1.5 mg copper/kg (deficient) and 6.0 mg Cu/kg (adequate) were supplemented with molybdenum (500 mg/kg diet). Starting at week 0 rats were killed weekly for up to 6 weeks and the caeruloplasmin activity of plasma, the Cu concentration of plasma, liver and kidney and the Mo concentration of liver and kidney were determined. The experiment was repeated with rats fed on diets of the same composition but given additional Cu for periods of 2 weeks. Cu was given orally by increasing dietary Cu to 6.0 mg/kg and 25.0 mg/kg for Cu-deficient and Cu-adequate rats respectively or intraperitoneally by injecting 75 micrograms and 250 micrograms every second day to Cu-deficient and Cu-adequate rats respectively. 2. After Mo administration to Cu-deficient rats plasma and kidney Cu and liver and kidney Mo increased but caeruloplasmin activity and liver Cu decreased. In Cu-adequate rats plasma, liver and kidney Cu and liver and kidney Mo increased to much higher levels than in Cu-deficient rats. Caeruloplasmin activity was not affected. Fluctuations in plasma Cu and kidney Mo were correlated closely. 3. No qualitative difference between the effect of oral or intraperitoneal Cu administered to Mo-treated Cu-deficient or Cu-adequate rats was found. In Cu-deficient Mo-supplemented rats additional Cu increased plasma Cu, caeruloplasmin activity and liver and kidney Cu and Mo. In Cu-adequate Mo-supplemented rats additional Cu decreased plasma Cu and liver and kidney Mo and increased caeruloplasmin activity and kidney cu and, to a minor extent, liver Cu. 4. In veiw of the assumption that in rats a Cu, Mo and S containing compound, related to Cu-thiomolybdate, may be formed in vivo the results suggest that cu binds to the Mo-S part of the compound; when this compound is formed in the gastro-intestinal tract it can not be absorbed and when it is formed at systemic sites it changes the Cu distribution.
 ...
PMID:Changes in the distribution of copper and molybdenum after Mo administration and subsequent additional oral or intraperitoneal Cu administration to rats. 711 61

1. Male WAG/Cpb inbred rats fed on rations with approximately 1.5 mg copper/kg (deficient), 6.0 mg Cu/kg (adequate) and 25.0 mg Cu/kg (excess) were supplemented with varying amounts of molybdenum (0, 50, 150 and 500 mg/kg diet) and the effect on the Cu concentration of blood, plasma, liver and kidney, the caeruloplasmin activity of plasma and the Mo concentration of liver and kidney were studied. 2. Mo increased the Cu concentration of blood, plasma, liver and kidney and the Mo concentration of liver and kidney. 3. In the plasma of Mo-supplemented rats the presence of a Cu-containing fraction was demonstrated, the Cu of which did not react with dithiocarbamate and was not related to caeruloplasmin. The Cu in this fraction was not able to increase the caeruloplasmin activity in the plasma of Cu-deficient Mo-supplemented rats. The Cu concentration of the erythrocytes did not seem to have been increased by the Mo treatment. 4. When compared to Cu-adequate rats the effect of Mo on the Cu distribution was reduced both by Cu deficiency and Cu excess. This decreased effect of Mo was explained by reduced uptake or retention of Mo in the body as observed in the liver and kidney.
 ...
PMID:The influence of molybdenum on the copper metabolism of the rat at different Cu levels of the diet. 737 40